Cell Biochemistry and Biophysics

, Volume 59, Issue 1, pp 7–12

Efficacy of Amifostine in Treating Patients with Idiopathic Thrombocytopenia Purpura

  • Hui Fan
  • Hong-Li Zhu
  • Su-Xia Li
  • Xue-Chun Lu
  • Bing Zhai
  • Bo Guo
  • Shan-Qian Yao
  • Yang Liu
Original research

Abstract

Idiopathic Thrombocytopenic Purpura (ITP) is an autoimmune disease characterized by the production of antibodies against platelet surface antigens, resulting in platelet destruction. ITP is generally treated using glucocorticoids, splenectomy, immunosuppressants, platelet transfusions, and also rituxan and rituximab. However, as these treatments are not effective in some refractory ITP patients, especially the elderly, who are also at greater risk of cerebral hemorrhage, we have undertaken this study to find a safe and effective way of treating these patients. In a clinical protocol, we have examined the efficacy of the cytoprotective adjuvant, amifostine, on 24 ITP patients, consisting of 21 Chinese (age: 13–92 years), and 3 Caucasians (age: 46–73 years). In order to prevent the side effects associated with amifostine treatment, an alternative dosing and anti-emetic regimen was developed as part of this protocol, which significantly improved patient acceptance. The protocol consisted of daily intravenous infusions of amifostine 5 × 400 mg per week, for a total of 4–5 weeks. All the patients experienced a long-lasting and continuing remission, defined as platelet counts greater than 100,000. Two patients relapsed: one after an upper respiratory tract infection, and another due to Helicobacter pylori. However, both these patients had complete remission, after they were treated again with amifostine. In this clinical study, we report for the first time, the successful use of amifostine for ITP treatment in refractory patients. In conclusion, amifostine may have good therapeutic effect on ITP patients, especially in refractory and/or elderly. The long-term clinical outcome and the mechanism of action of this drug still need further investigation.

Keywords

Amifostine Idiopathic thrombocytopenia purpura Myelodysplastic syndrome Platelets 

References

  1. 1.
    Cines, D. B., & McMillan, R. (2005). Management of adult idiopathic thrombocytopenic purpura. Annual Review of Medicine, 56, 425–442.CrossRefPubMedGoogle Scholar
  2. 2.
    McMillan, R., Wang, L., Tomer, A., Nichol, J., & Pistillo, J. (2004). Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood, 103, 1364–1369.CrossRefPubMedGoogle Scholar
  3. 3.
    Stevens, W., Koene, H., Zwaginga, J. J., & Vreugdenhil, G. (2006). Chronic idiopathic thrombocytopenic purpura: present strategy, guidelines and new insights. Netherlands Journal of Medicine, 64, 356–363.PubMedGoogle Scholar
  4. 4.
    Bussel, J. B. (2009). Traditional and new approaches to the management of immune thrombocytopenia: issues of when and who to treat. Hematology/Oncology Clinics of North America, 23, 1329–1341.CrossRefPubMedGoogle Scholar
  5. 5.
    Rodeghiero, F. (2008). First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat. European Journal of Haematology. Supplementum, 69, 19–26.PubMedGoogle Scholar
  6. 6.
    Culy, C. R., & Spencer, C. M. (2001). Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs, 61, 641–684.CrossRefPubMedGoogle Scholar
  7. 7.
    Raza, A., Qawi, H., Lisak, L., Andric, T., Dar, S., et al. (2000). Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood, 95, 1580–1587.PubMedGoogle Scholar
  8. 8.
    Li, S. X., Zhu, H. L., Lu, X. C., Fan, H., Yao, S. Q., et al. (2007). Amifostine used in the treatment of patients with myelodysplastic syndrome. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 15, 86–90.PubMedGoogle Scholar
  9. 9.
    Lu, X. C., Zhu, H. L., Yao, S. Q., Fan, H., Zhuang, X. M., et al. (2005). Short-term curative effect of amifostine combined with rhEPO on aged patients wilh myelodysplastic syndrome. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 13, 440–442.PubMedGoogle Scholar
  10. 10.
    Cines, D. B., & Blanchette, V. S. (2002). Immune thrombocytopenic purpura. New England Journal of Medicine, 346, 995–1008.CrossRefPubMedGoogle Scholar
  11. 11.
    Newland, A. (2008). Emerging strategies to treat chronic immune thrombocytopenic purpura. European Journal of Haematology. Supplementum, 69, 27–33.PubMedGoogle Scholar
  12. 12.
    Ben-Yehuda, D., Gillis, S., & Eldor, A. (1994). Clinical and therapeutic experience in 712 Israeli patients with idiopathic thrombocytopenic purpura. Israeli ITP Study Group. Acta Haematologica, 91, 1–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Michel, M., Cooper, N., Jean, C., Frissora, C., & Bussel, J. B. (2004). Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura? Blood, 103, 890–896.CrossRefPubMedGoogle Scholar
  14. 14.
    Bussel, J. B., Kuter, D. J., George, J. N., McMillan, R., Aledort, L. M., et al. (2006). AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. New England Journal of Medicine, 355, 1672–1681.CrossRefPubMedGoogle Scholar
  15. 15.
    Dimopoulou, M. N., Gandhi, S., Ghevaert, C., Chakraverty, R., Fielding, A., et al. (2007). Successful treatment of autoimmune lymphoproliferative syndrome and refractory autoimmune thrombocytopenic purpura with a reduced intensity conditioning stem cell transplantation followed by donor lymphocyte infusion. Bone Marrow Transplantation, 40, 605–606.CrossRefPubMedGoogle Scholar
  16. 16.
    Marcu, L. G. (2009). The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy. European Journal of Cancer Care (England), 18, 116–123.CrossRefGoogle Scholar
  17. 17.
    Winczura P, Jassem J (2009) Combined treatment with cytoprotective agents and radiotherapy. Cancer Treat Rev.Google Scholar
  18. 18.
    Santini, V., & Giles, F. J. (1999). The potential of amifostine: From cytoprotectant to therapeutic agent. Haematologica, 84, 1035–1042.PubMedGoogle Scholar
  19. 19.
    Viniou, N., Terpos, E., Galanopoulos, A., Kritikou-Griva, E., Akel, S., et al. (2002). Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response. Annals of Hematology, 81, 182–186.CrossRefPubMedGoogle Scholar
  20. 20.
    Fan, H., Zhu, H. L., Yao, S. Q., Lu, X. C., Zhuang, X. M., et al. (2006). Early effect of amifostine in treating aged patients with idiopathic thrombocytopenia purpura. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 14, 301–303.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Hui Fan
    • 1
  • Hong-Li Zhu
    • 1
  • Su-Xia Li
    • 1
  • Xue-Chun Lu
    • 1
  • Bing Zhai
    • 1
  • Bo Guo
    • 1
  • Shan-Qian Yao
    • 1
  • Yang Liu
    • 1
  1. 1.Department of Geriatric HaematologyGeneral Hospital of PLABeijingChina

Personalised recommendations